Does the 505(b)(2) Regulatory Pathway for NDA's Provide an Adequate ROI?

I have a post on LinkedIn where I share a few thoughts about the benefits and limitations of developing drugs using the 505(b)(2) regulatory pathway. Hardly a week goes by without a pharmaceutical company expressing the desire to reap the benefits of developing a drug using the “505(b)(2) regulatory pathway”. What are 505(b)(2) new drug applications (NDAs) and do they really provide a meaningful advantage to pharmaceutical companies?

For the full post on LinkedIn, please see: http://tinyurl.com/j9fh2zn

 

Be the first to comment

Please check your e-mail for a link to activate your SDEE account.

Attend SDEE Events Donate | Sponsor SDEE Become a Member

Connect with SDEE

Sign Up for SDEE Newsletter


SDEE PLATINUM SPONSORS

ALT San Diego

SDEE GOLD SPONSORS

Alexandria

Ted Jacobs
Managing Director
Cushman & Wakefield

SDEE SILVER SPONSORS

Takeda San Diego

SDEE BRONZE SPONSORS

Duane Morris MaxCyte Wagenknecht Barney and Barney

SDEE is a nonprofit 501(c)(3) organization founded by local San Diego entrepreneurs
in order to provide a voice for the early stage start-up, to support new entrepreneurs and their companies,
and to sponsor networking and educational events
to help develop the skills necessary to bring funding, business, and jobs to the San Diego area.

© 2015 San Diego Entrepreneurs Exchange. All Rights Reserved